216 related articles for article (PubMed ID: 35623614)
1. Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center.
Lindsay J; Krantz EM; Morris J; Sweet A; Tverdek F; Joshi A; Yeh R; Hill JA; Greenwood M; Chen SC; Kong DCM; Slavin M; Pergam SA; Liu C
Transplant Cell Ther; 2022 Aug; 28(8):511.e1-511.e10. PubMed ID: 35623614
[TBL] [Abstract][Full Text] [Related]
2. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole.
Shoham S; Ostrander D; Marr K
Transpl Infect Dis; 2015 Jun; 17(3):493-6. PubMed ID: 25846433
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
[TBL] [Abstract][Full Text] [Related]
6. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
[TBL] [Abstract][Full Text] [Related]
8. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients.
Kraljevic M; Khanna N; Medinger M; Passweg J; Masouridi-Levrat S; Chalandon Y; Mueller NJ; Schanz U; Vernaz N; Van Delden C; Neofytos D;
Med Mycol; 2021 Jul; 59(7):701-711. PubMed ID: 33381803
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
10. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Herity LB; Cruz OA; Aziz MT
J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
[TBL] [Abstract][Full Text] [Related]
12. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
13. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
[TBL] [Abstract][Full Text] [Related]
14. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.
Zeng G; Wang L; Shi L; Li H; Zhu M; Luo J; Zhang Z
Eur J Clin Pharmacol; 2020 Apr; 76(4):515-523. PubMed ID: 31932875
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Passweg JR; Baldomero H; Ansari M; Arber C; Chalandon Y; Daskalakis M; Diepold M; Diesch-Furlanetto T; Duchosal MA; Gerull S; Güngör T; Heim D; Hitz F; Holbro A; Masouridi-Levrat S; Nair G; Novak U; Pabst T; Renner C; Stussi G; Schneidawind D; Schanz U; Wannesson L; Halter JP;
Hematol Oncol; 2024 Jan; 42(1):e3241. PubMed ID: 38058031
[TBL] [Abstract][Full Text] [Related]
16. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections.
Chin A; Pergam SA; Fredricks DN; Hoofnagle AN; Baker KK; Jain R
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760896
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir.
Terrier J; Zanella MC; Masouridi-Levrat S; Kronig I; Chalandon Y; Vernaz N; Van Delden C; Papanicolaou G; Neofytos D
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782007
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.
Amsden JR; Gubbins PO; McConnell S; Anaissie E
Antimicrob Agents Chemother; 2013 Jul; 57(7):3420-3. PubMed ID: 23629717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
